Our group has previously demonstrated that NRP2 protein was a predictive factor for the outcome in a special patient cohort with several comorbidities that suffered from T2–4 or high risk T1 BLCA and that were treated with TURBT and adjuvant radiochemotherapy. This evidence concerns the gene NRP2 and bladder transitional cell carcinoma.